Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 5771.

https://doi.org/10.1182/blood-2019-122958

Published: 2019

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Sandra Malak, MD, Pascale Cony-Makhoul, MD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Philippe Rodon, MD, Fabienne Vacheret, MD, Barraco Fiorenza, MD, Francoise Boyer, MD, Katell Le Du, MD, Loic Garcon, MD PhD, Francois Lefrere, MD, Mathieu Wemeau, MD, Valerie Ugo, MD PhD, Jean-Jacques Kiladjian, MD PhD, Lydia Roy, MD

Blood (2016) 128 (22): 3123.

https://doi.org/10.1182/blood.V128.22.3123.3123

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Blood (2016) 127 (3): 333–342.

https://doi.org/10.1182/blood-2015-07-661983

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Christine Dosquet, Stephane Giraudier, Marie-Hélène Schlageter, Jean-Christophe Ianotto, Mohammed A. Yassin, Nader Al-Dewik, Serge Carillo, Eric Legouffe, Valerie Ugo, Christine Chomienne, Jean-Jacques Kiladjian

Blood (2015) 126 (24): 2585–2591.

https://doi.org/10.1182/blood-2015-07-659060

Published: 2015

Journal Articles

Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

Damien Luque Paz, MD, Aurelie Chauveau, MD, Caroline Buors, MD, Jean-Christophe Ianotto, MD, Francoise Boyer, MD, Laura Samaison, MD, Claude Ferec, MD PhD, Cedric Le Marechal, MD PhD, Paul Gueguen, MD, Valerie Ugo, MD PhD

Blood (2015) 126 (23): 2808.

https://doi.org/10.1182/blood.V126.23.2808.2808

Published: 2015

Journal Articles

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Christine Dosquet, MD PhD, Marie-Helene Schlageter, Valérie Ugo, MD PhD, Jean-Christophe Ianotto, MD, Mohamed A. Yassin, MBBS ,MSc,CABM,FACP, Nader Dewik, PhD, Serge Carillo, PhD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 407.

https://doi.org/10.1182/blood.V124.21.407.407

Published: 2014

Journal Articles

Incidence and Localization of Vascular Events in a Well Characterized Cohort of 477 Patients with Myeloproliferative Neoplasms

Aurélie Chauveau, MD, Damien Luque Paz, MDstudent, Ronan Le Calloch, MDStudent, Caroline Buors, MD, Lydie Lecucq, Dominique Mottier, MD PhD, Valérie Ugo, MD PhD, Jean-Christophe Ianotto, MD

Blood (2014) 124 (21): 1854.

https://doi.org/10.1182/blood.V124.21.1854.1854

Published: 2014

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Sequential Measurement Of JAK2 V617F Allele Burden In Polycythemia Vera and Essential Thrombocythemia Reveals Different Evolution Profiles: First Results Of Jaksuivi, a Multicentre Study By The French Intergroup Of Myeloproliferative Neoplasms (FIM)

Caroline Buors, Françoise Boyer, Aline Tanguy-Schmidt, Aurélie Chauveau, Lydia Roy, MD, Jean-Claude Chomel, PharmD, PhD, Thierry Lamy, MD, PhD, Olivier Fardel, Olivier Herault, MD, PhD, Laura Samaison, Valérie Ugo, MD, PhD, Jean-Christophe Ianotto, MD

Blood (2013) 122 (21): 1593.

https://doi.org/10.1182/blood.V122.21.1593.1593

Published: 2013

Journal Articles

Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy

Divi Cornec, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin, Thierry Marhadour, Valérie Ugo, Christian Berthou, Nathalie Douet-Guilbert, Alain Saraux

Blood (2013) 122 (9): 1583–1586.

https://doi.org/10.1182/blood-2013-03-491464

Published: 2013

Journal Articles

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Sabrina Dupont, Aline Massé, Chloé James, Irène Teyssandier, Yann Lécluse, Frédéric Larbret, Valérie Ugo, Patrick Saulnier, Serge Koscielny, Jean Pierre Le Couédic, Nicole Casadevall, William Vainchenker, François Delhommeau

Blood (2007) 110 (3): 1013–1021.

https://doi.org/10.1182/blood-2006-10-054940

Published: 2007

Includes: Supplemental data

Journal Articles

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Jerome Tamburini, Caroline Elie, Valérie Bardet, Nicolas Chapuis, Sophie Park, Philippe Broët, Pascale Cornillet-Lefebvre, Bruno Lioure, Valérie Ugo, Odile Blanchet, Norbert Ifrah, Francis Witz, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Blood (2007) 110 (3): 1025–1028.

https://doi.org/10.1182/blood-2006-12-061283

Published: 2007

NARROW

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Incidence and Localization of Vascular Events in a Well Characterized Cohort of 477 Patients with Myeloproliferative Neoplasms

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Sequential Measurement Of JAK2 V617F Allele Burden In Polycythemia Vera and Essential Thrombocythemia Reveals Different Evolution Profiles: First Results Of Jaksuivi, a Multicentre Study By The French Intergroup Of Myeloproliferative Neoplasms (FIM)

Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only